---
title: EU Regulator Backs Lung Cancer Drug Sintilimab on the China-Only Trial the FDA Rejected
description: The EMA's CHMP backed Innovent's lung cancer drug sintilimab on ORIENT-11, the all-China trial the FDA turned down in 2022 over single-country data.
author: Darie Nani (Editor-in-Chief)
date: 2026-11-16T12:28:46.473Z
updated: 2026-11-16T12:28:46.498Z
canonical: https://www.sovereignmagazine.com/article/eu-backs-sintilimab-china-only-trial-fda-rejected
image: https://cdn.nanimediahouse.com/european-medicines-agency-amsterdam-591749.webp
categories: EU Focus
content_type: News
region: Global
publication: Sovereign Magazine
schema_type: Article
about:
  - type: Organization
    name: Innovent Biologics
    description: Suzhou-based biopharmaceutical company, listed in Hong Kong, that developed the PD-1 immunotherapy sintilimab.
    url: https://www.innoventbio.com
---

The European Medicines Agency's human medicines committee, the CHMP, [recommended on 12 November](https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2026) that the EU approve sintilimab, the lung cancer immunotherapy developed by China's Innovent Biologics. Innovent says the committee based its positive opinion on ORIENT-11, a 397-patient trial run entirely in China. In March 2022 the US Food and Drug Administration turned down an application based on the same trial and asked for a new trial run across several regions.

## The CHMP Recommended Sintilimab With Chemotherapy as a First Treatment for Non-Squamous Lung Cancer

The committee recommended sintilimab, under the EU brand name Zybrivo, with pemetrexed and platinum-based chemotherapy for adults with non-squamous non-small cell lung cancer whose tumours have no EGFR or ALK genomic aberrations. The [indication](https://www.ema.europa.eu/en/medicines/human/EPAR/zybrivo) covers metastatic disease and locally advanced disease that cannot be treated with curative surgery or chemoradiation. The EMA describes the benefit as an improvement in progression-free survival seen in a randomised, multicentre, double-blind, placebo-controlled study.

In ORIENT-11, patients were randomised two to one to receive sintilimab or a placebo, each with the same chemotherapy, and progression-free survival assessed by blinded independent review was the primary endpoint. Innovent said patients on sintilimab had a 52% lower hazard of disease progression or death, with median progression-free survival of 8.9 months against 5.0 months, and a 35% lower hazard of death, with median overall survival of 24.2 months against 16.8 months. The company said no new safety signals were found. The trial is [registered as NCT03607539](https://clinicaltrials.gov/study/NCT03607539), with China as its only location.

It is the first positive CHMP opinion Innovent has received. Dr Hui Zhou, Innovent's chief R&D officer of oncology, said the opinion "brings us a step closer to serving patients in Europe".

## The FDA Rejected the Same Trial in 2022, and Lilly Later Handed the Rights Back to Innovent

Innovent filed the US application in 2021, when Eli Lilly held the rights to sintilimab outside China under a 2020 alliance. On 10 February 2022 the FDA's Oncologic Drugs Advisory Committee voted 14 to 1 against relying on single-country foreign data for the application.

In its briefing documents, the FDA said the ORIENT-11 population "does not reflect the diversity of the American population", that sintilimab "does not fulfill an unmet need for US patients with NSCLC", and that the trial "was powered for PFS, without statistical testing for OS". Committee members were also uneasy that patients in the trial did not receive pembrolizumab (Keytruda), which has been shown to extend overall survival.

All of the trial's patients were Asian, a group that makes up 7% of the US population. Richard Pazdur, then director of the FDA's Oncology Center of Excellence, who did not vote, noted the lack of diversity. "Single country submission is a step backward in achieving the racial diversity that we need in the United States," he said.

In its complete response letter in March 2022, the FDA recommended an additional [multiregional trial](https://www.sovereignmagazine.com/article/china-approves-tinengotinib-fgfr-bile-duct-cancer) comparing sintilimab plus chemotherapy with the standard of care for first-line metastatic non-small cell lung cancer, with a non-inferiority design and overall survival as the endpoint. Lilly's licence for markets outside China was terminated and the rights reverted to Innovent in October 2022, according to a Lilly filing.

## The FDA's Rule Governs Approval on Foreign Data Alone, While EMA Guidance Asks Whether Extra EU Trials Are Needed

Under [21 CFR 314.106](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-D/section-314.106), the FDA may approve an application based solely on foreign clinical data if the data apply to the US population and US medical practice, if the studies were done by clinical investigators of recognised competence, and if the FDA can treat the data as valid without an on-site inspection, or can validate them through an inspection or other means.

The EMA works from a [reflection paper on extrapolating results from clinical studies conducted outside the EU](https://www.ema.europa.eu/en/extrapolation-results-clinical-studies-conducted-outside-europe-eu-population-scientific-guideline) to the EU population, in effect since 1 May 2010. The agency describes the paper as a reinforcement of ICH E5, the international guideline on ethnic factors in the acceptability of foreign clinical data, and says it is "to be used when deciding whether certain clinical trials conducted in a specific area of the world would be relevant to the EU setting or if there are reasons to perform additional clinical trials within the EU".

## FDA Leaders Said in September That Foreign Trials Face More Scrutiny, as Big Pharma Licenses More Drugs From China

Four senior FDA officials, among them R. Angelo de Claro, director of the Oncology Center of Excellence, and the acting heads of the agency's drug and biologics centres, wrote in a 2 September post on the FDA Voices blog that "Trials that fail to enroll American patients can be less easily generalized" and that "Companies should not assume that there is a lower probability of FDA inspection by conducting studies abroad." They said that "for some foreign inspections of clinical trial sites, the FDA has been denied access", and that the agency is adding resources for foreign inspections under its Bioresearch Monitoring programme. The officials also wrote that "Many foreign research institutions produce clinical data of the highest quality".

Chinese biotechs "accounted for 40% of all assets in-licensed by big pharma in 2025", according to [an analysis by the data company IQVIA](https://www.iqvia.com/locations/emea/blogs/2026/07/biopharma-ma-mid-year-2026-update), so the FDA's tighter line on foreign trials reaches a large part of [big pharma's pipeline](https://www.sovereignmagazine.com/article/windward-bio-ipo-price). IQVIA says therapeutic in-licensing deals involving Chinese-originated assets, excluding AI-focused partnerships, reached $92 billion in the first half of 2026, 88% of the 2025 total.

## The European Commission Still Has to Grant the Authorisation

The European Commission has yet to decide on the CHMP's recommendation. If it grants marketing authorisation, Zybrivo will be authorised in all 27 EU member states and in Iceland, Norway and Liechtenstein. The EMA has so far published only a summary of the committee's opinion, so its reasoning on the China-only data is not yet public; the detailed product information follows authorisation.

More on Innovent Biologics is at [innoventbio.com](https://www.innoventbio.com).

## FAQ

**Q: Who is the applicant for sintilimab in the EU?**
The EMA lists Fortvita Biologics (Ireland) Limited as the applicant for Zybrivo, under EMA product number EMEA/H/C/006743.

**Q: When will the European Commission decide on sintilimab?**
Innovent expects the Commission's final decision "in the coming months". The EMA will publish the summary of product characteristics, the detailed prescribing information, in all official EU languages once the authorisation is granted.

**Q: What is sintilimab?**
Sintilimab is a fully human IgG4 monoclonal antibody. It binds PD-1, a protein that can stop the immune system from attacking cancer cells, and blocks its interaction with the ligands PD-L1 and PD-L2. In the EU it would be supplied as a 100 mg concentrate for infusion.

**Q: Is sintilimab approved in China?**
Yes, for ten indications: three uses in non-small cell lung cancer, plus hepatocellular carcinoma, gastric or gastroesophageal junction adenocarcinoma, oesophageal squamous cell cancer, endometrial cancer, colon cancer, renal cell carcinoma and classical Hodgkin's lymphoma. Innovent says about 3 million patients in China have been treated with it.
